Challenges and opportunities for checkpoint blockade in T-cell lymphoproliferative disorders

Por Phillips, Tycel, Devata, Sumana, Wilcox, Ryan A.
Publicado no J Immunother Cancer (2016)

Survival Following Salvage Therapy for Primary Refractory Peripheral T-Cell Lymphomas (PTCL)

Por Zhang, Janie Y., Briski, Robert, Devata, Sumana, Kaminski, Mark S., Phillips, Tycel J., Mayer, Tera L., Bailey, Nathanael G., Wilcox, Ryan A.
Publicado no Am J Hematol (2017)

Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004)

Por Wang, Michael, Schuster, Stephen J., Phillips, Tycel, Lossos, Izidore S., Goy, Andre, Rule, Simon, Hamadani, Mehdi, Ghosh, Nilanjan, Reeder, Craig B., Barnett, Evelyn, Bravo, Marie-Laure Casadebaig, Martin, Peter
Publicado no J Hematol Oncol (2017)

Polo-like-kinase 1 (PLK-1) and c-myc inhibition with the dual kinase-bromodomain inhibitor volasertib in aggressive lymphomas

Por Murga-Zamalloa, Carlos, Polk, Avery, Hanel, Walter, Chowdhury, Pinki, Brown, Noah, Hristov, Alexandra C., Bailey, Nathanael G., Wang, Tianjiao, Phillips, Tycel, Devata, Sumana, Poonnen, Pradeep, Gomez-Gelvez, Juan, Inamdar, Kedar V., Wilcox, Ryan A.
Publicado no Oncotarget (2017)

RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106

Por Chen, Robert W., Li, Hongli, Bernstein, Steven H., Kahwash, Samir, Rimsza, Lisa M., Forman, Stephen J., Constine, Louis, Shea, Thomas C., Cashen, Amanda F., Blum, Kristie A., Fenske, Timothy S., Barr, Paul M., Phillips, Tycel, Leblanc, Michael, Fisher, Richard I., Cheson, Bruce D., Smith, Sonali M., Faham, Malek, Wilkins, Jennifer, Leonard, John P., Kahl, Brad S., Friedberg, Jonathan W.
Publicado no Br J Haematol (2016)